Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Earnings Results, Meets Estimates

Posted by George Bondi on Jul 28th, 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30, FiscalAI reports. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%.

Kiniksa Pharmaceuticals International Stock Up 1.1%

KNSA opened at $63.53 on Tuesday. Kiniksa Pharmaceuticals International has a twelve month low of $26.51 and a twelve month high of $67.53. The company’s 50-day moving average price is $57.07 and its two-hundred day moving average price is $50.18. The stock has a market cap of $4.89 billion, a price-to-earnings ratio of 70.59 and a beta of 0.07.

Analyst Ratings Changes

KNSA has been the topic of several research reports. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. The Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 23rd. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $68.00.

Read Our Latest Analysis on Kiniksa Pharmaceuticals International

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the sale, the chief executive officer owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares in the company, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 131,674 shares of company stock valued at $7,094,671. 51.98% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds have recently made changes to their positions in KNSA. Virtu Financial LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at $267,000. Invesco Ltd. grew its stake in shares of Kiniksa Pharmaceuticals International by 25.9% during the 4th quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock worth $1,334,000 after acquiring an additional 6,656 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares during the period. Empowered Funds LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $51,000. Finally, XTX Topco Ltd purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $291,000. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

(Get Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.